271 related articles for article (PubMed ID: 8331897)
1. Detection of MYCN gene amplification and deletions of chromosome 1p in neuroblastoma by in situ hybridization using routine histologic sections.
Leong PK; Thorner P; Yeger H; Ng K; Zhang Z; Squire J
Lab Invest; 1993 Jul; 69(1):43-50. PubMed ID: 8331897
[TBL] [Abstract][Full Text] [Related]
2. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
[TBL] [Abstract][Full Text] [Related]
3. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
[TBL] [Abstract][Full Text] [Related]
4. Analysis of genomic imprinting at 1p35-36 in neuroblastoma.
Hogarty MD; Maris JM; White PS; Guo C; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):52-5. PubMed ID: 11464906
[TBL] [Abstract][Full Text] [Related]
5. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.
Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P
Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551
[TBL] [Abstract][Full Text] [Related]
6. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
7. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
[TBL] [Abstract][Full Text] [Related]
8. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
Gehring M; Berthold F; Edler L; Schwab M; Amler LC
Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
[TBL] [Abstract][Full Text] [Related]
9. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
Ohtsu K; Hiyama E; Ichikawa T; Matsuura Y; Yokoyama T
Clin Cancer Res; 1997 Jul; 3(7):1221-8. PubMed ID: 9815803
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
[TBL] [Abstract][Full Text] [Related]
11. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
[TBL] [Abstract][Full Text] [Related]
12. Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping.
Stark B; Jeison M; Bar-Am I; Glaser-Gabay L; Mardoukh J; Luria D; Feinmesser M; Goshen Y; Stein J; Abramov A; Zaizov R; Yaniv I
Genes Chromosomes Cancer; 2002 Jul; 34(3):313-24. PubMed ID: 12007192
[TBL] [Abstract][Full Text] [Related]
13. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
[TBL] [Abstract][Full Text] [Related]
14. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
[TBL] [Abstract][Full Text] [Related]
15. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma.
Hiyama E; Hiyama K; Yokoyama T; Fukuba I; Yamaoka H; Shay JW; Matsuura Y
Clin Cancer Res; 1999 Mar; 5(3):601-9. PubMed ID: 10100712
[TBL] [Abstract][Full Text] [Related]
16. Two-dimensional DNA electrophoresis identifies novel CpG islands frequently coamplified with MYCN in neuroblastoma.
Wimmer K; Zhu XX; Lamb BJ; Kuick R; Ambros P; Kovar H; Thoraval D; Elkahloun A; Meltzer P; Hanash SM
Med Pediatr Oncol; 2001 Jan; 36(1):75-9. PubMed ID: 11464910
[TBL] [Abstract][Full Text] [Related]
17. Automatic quantification of gene amplification in clinical samples by IQ-FISH.
Narath R; Lörch T; Rudas M; Ambros PF
Cytometry B Clin Cytom; 2004 Jan; 57(1):15-22. PubMed ID: 14696059
[TBL] [Abstract][Full Text] [Related]
18. An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis.
Spieker N; Beitsma M; van Sluis P; Roobeek I; den Dunnen JT; Speleman F; Caron H; Versteeg R
Genes Chromosomes Cancer; 2000 Feb; 27(2):143-52. PubMed ID: 10612802
[TBL] [Abstract][Full Text] [Related]
19. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
[TBL] [Abstract][Full Text] [Related]
20. [The neuroblastoma, "enfant terrible" among pediatric tumors].
Laureys G
Verh K Acad Geneeskd Belg; 2003; 65(1):5-23; discussion 23-8. PubMed ID: 12802894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
